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Reply
We are grateful for the comments of Dr. Thombs and colleagues.
In our recent study we set out to examine the effects of the
timing of assessment of depression on mortality after myocardial
infarction (MI) (1). We showed that depression before MI,
whether chronic or not, does not increase cardiac mortality. This
was a surprise to us because we anticipated that pre-MI depression,
which was associated with chronic social difficulties (2) and likely
to be persistent (3), would be related to increased mortality after
MI. We have published this paper to make it clear that this is not
the case. Furthermore, we found that depression present 12
months after MI did not predict subsequent mortality.
We acknowledge that our study alone does not provide direct
evidence for a window of effect for depression predicting increased
mortality. However, if we contrast our findings with those studies
showing an association of depression in the days or weeks after MI
with post-MI mortality, it seems likely that it is those people who
develop depression in the period immediately after MI that are at
increased risk of cardiac mortality. Patients developing depression
after an acute cardiac event have been shown to be at increased risk
of dying in previous studies (4,5), and we are now looking at this
particular question in our own data.
Our negative findings for depression cannot be dismissed as
resulting from our statistical methods. We accept the point that
the number of independent variables included was large, but our
finding was the same in the uncontrolled (univariate) comparison.
Furthermore, our findings remained stable if we used backward
elimination of variables, so that the number of independent
variables in the final model was few (hazard ratio [HR] for
depression 0.86, p 0.60) or if we performed our analyses using
fewer variables (e.g., age, gender, educational level, degree of
cardiac dysfunction, and revascularization procedures (4), HR for
depression 1.02, p 0.94). Our findings also remained negative
when we did not control for medications at discharge (HR for
depression  0.87, p  0.62).
Our finding that subjects with depression at both baseline and
12 months had an apparent survival advantage is confusing and
counterintuitive. We can clarify here that, compared with the
remainder, this group was more likely to be female gender (49% vs.
28%) and younger (mean age 45.3 vs. 60.8 years). Controlling for
age and gender alone eliminated the association between persistent
depression and subsequent mortality (p  0.97).
The fact that depression that predates the MI and persists
through the post-MI period does not predict mortality is extremely
important. It supports the suggestion that it is not depression alone
that is having the adverse impact on survival but that some
additional factor interacts with depression to create this effect
(6,7). Rather than ignoring the heterogeneity in previous findings,
future research should continue to examine possible reasons for
this heterogeneity as it may identify vulnerable subgroups and
explain how and why depression has this effect on survival.
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Eliminating Plaque Angiogenesis
We have read with great interest the article by Kolodgie et al. (1)
focusing on elimination of intraplaque angiogenesis. It seems that
neovascularization within the vessel wall plays an important role in
plaque destabilization, and it is a determinant of vulnerability.
The beneficial effect of statins in patients with atherosclerotic
disease is well established. This effect goes beyond lipid lowering,
because statins also have other effects, which is why statins are
considered pleiotropic. One of these is its effect on angiogenesis.
We recently presented that patients on statin treatment have
reduced intraplaque angiogenesis in their carotid endarterectomy
specimens when compared with patients not receiving this kind of
drug (2). This finding provides a new insight to the statins’
pathophysiologic mechanism of action. The fact that it was a
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cross-sectional, retrospective study without randomization cannot
lead us to any causal conclusions about statins and intraplaque
angiogenesis. However, there are strong indications favoring that
hypothesis. Vascular endothelial growth factor is a well-recognized
and potent angiogenetic factor. It is known that pravastatin, but
also fenofibrate, reduces vascular endothelial growth factor plasma
levels in humans (3).
These findings raise the question of whether statins are the
antiangiogenetic factor for which we are searching. To answer this
question, further investigation is needed, and maybe it is time for
a randomized trial with standard dose and duration of treatment to
test the effect on intraplaque angiogenesis.
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Reply
Koutouzis et al. (1) propose the paradigm of statins eliminating
plaque angiogenesis and, thus, lesion instability. These authors
recently showed pathologic data of reduced microvascular density
in carotid plaques from patients receiving statins at least 3 months.
However, direct evidence of decreased intraplaque angiogenesis
attributed to statins and clinical improvement is lacking. More-
over, magnetic resonance imaging shows statins to be more
effective in debulking nonhemorrhagic plaques as necrotic core
volume in lesions with intraplaque hemorrhage increases, despite
statin use (2). Large-scale clinical trials in parallel angiogenic disor-
ders such as age-related macular degeneration (3) or tumor growth (4)
have failed to show a consistent association between statins and
disease regression. These results are in opposition to the potent
antiangiogenic effects of statins in angiogenic assays (5) or animal
models (6).
Although statins down-regulate various gene products that
mediate cell proliferation, including vascular endothelial growth
factor (7), there is an increasing redundancy of angiogenic factors
creating the potential to circumvent drugs targeting specific path-
ways (8). Further, the expression of pro- and antiangiogenic
mediators is likely dependent on lesion stage, possibly compromis-
ing the efficacy of a single drug. The identification of reliable
biomarkers or imaging methods to gauge the effectiveness of
antiangiogenic therapy also remains an obstacle because the cur-
rent end point is limited to evaluation of surgical tissue.
Finally, it is not clear whether decreased neovascularlization or
“normalization” of existing vessels is the more favorable approach
because the pathology is not dictated by the mere presence of
vessels, but by the fact that these structures are dysfunctional as
they are fragile and leaky. A normalized, less leaky vasculature,
characterized by a more restrictive basement membrane sur-
rounded by pericytes (9), may support a more favorable microen-
vironment promoting plaque stabilization.
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